Navigation Links
Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Date:1/23/2010

SINGAPORE, Jan. 23 /PRNewswire/ -- OrbusNeich announced that clinical data presented today at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.

Specifically, presentations delivered by Prof. Robbert de Winter, M.D., Ph.D., of the Academic Medical Center (AMC) in Amsterdam and Wojciech Wojakowski, M.D., from Medical University of Silesia in Poland focused on the use of the Genous Bio-engineered R stent in patients with bifurcation lesions and patients with non ST-segment elevation acute coronary syndrome.

Prof. de Winter's presentation, titled "One Year Clinical Outcome after Provisional T Stenting with the Endothelial Progenitor Cell Capturing Stent for Bifurcation Lesions," featured a single-center study with 178 patients that compared the Genous Bio-engineered R stent to a previous bare metal stent control group of 465 patients at the AMC.  A 32 percent reduction of the composite of cardiac death, myocardial infarction or target lesion revascularization was reported between these two groups. The cumulative rate of definite or probable stent thrombosis was reduced by 57 percent in the Genous Bio-engineered R stent-treated group compared to the control group.

"Bifurcation lesions remain a challenge for interventional cardiologists," said Prof. de Winter. "The Genous Bio-engineered R stent, with a low rate of stent thrombosis, is an alternative for this challenging patient group."

Dr. Wojakowski presented data on the JACK-EPC trial, a comparison of the efficiency of high dose atorvastatin and endothelial progenitor-capture stents versus bare metal stents, in the reduction of neointimal formation in patients w
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
2. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
3. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
4. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
7. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
8. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. New Clinical Study Finds Masimo Perfusion Index (PI) Predicts Low Systemic Blood Flow in Preterm Infants
11. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today ... diagnostic platform during a special event at the company,s ... , on September 5, 2014. The event, which will ... the ApolloDx website, www.apollodx.com .    ... testing," said Jared Bauer , Co-Founder and Managing ...
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- Pigs, hearts transplanted ... is twice as long as previously achieved, researchers report. ... ways to use animal organs to shorten transplant waiting ... genetically engineered piglets into baboons, abdomens. The genetic engineering ... response are what enabled the hearts to survive for ...
(Date:8/20/2014)... Thompson HealthDay Reporter WEDNESDAY, ... older women avoid a condition that causes a life-threatening irregular ... had a 10 percent lower risk of developing atrial fibrillation, ... the Aug. 20 issue of the Journal of the ... against the heart rhythm disorder even if they were obese, ...
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... and architecture firm Perkins Eastman is pleased ... and design services in China and ... internationally recognized Principal Richard Sprow AIA has ... continue his 40-year career in healthcare planning and design ...
(Date:8/20/2014)... A common approach to treating kidney failure by removing ... chances for people who suddenly developed the condition, in ... Pittsburgh School of Medicine. , Their findings, published online ... hemodialysis, an aggressive method that is standardly used for ... definitive benefit to the patient. , "Our findings question ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4
... and candidates faster, brings unprecedented functionality and ease of use to ... ... -- Dayak, the leading online recruiting marketplace used by ... more efficiently, today launched a new version of its user interface ...
... are trying to economize by choosing cheaper shipping methods , ... ... www.medisave.net ), a leading global medical equipment merchant with ... today announced that despite the global credit crunch, global sales have ...
... Indication this Year; Data Demonstrate High,Durable Response Rates ... a Rituximab-Containing Regimen, FRAZER, Pa., Nov. 3 ... U.S. Food and Drug Administration (FDA) has,approved TREANDA(R) ... with indolent B-cell non-Hodgkin,s lymphoma (NHL),that has progressed ...
... of Allergy and Infectious Diseases (NIAID) scientist Theodore E. ... with areas of brain tissue swelling in people infected ... form around dead, calcified cysts that result when larvae ... brain. The illness caused by T. solium ...
... provider team up to market ... final expense planning, ... Corporation International (NYSE: SCI ) have formed a,unique partnership through ... Final Expense insurance., This is an extraordinary combination of services ...
... 2008, JUPITER, Fla., Nov. 3 From November 15 -17, ... promote,National Smoke Out Day, November 20, and to promote her new ... -- MISS AMERICA 2008 KIRSTEN HAGLUND, WILL BE AVAILABLE ... NOVEMBER 15-17 TO PROMOTE SAVING LIVES, AND ...
Cached Medicine News:Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 2Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 3Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 2Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 3Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Health News:SLAICO and SCI Form Partnership 2
Replacement bulb for Vibratome light system....
The V-Block adapter is designed to allow round posts to be placed in the Vibratome vice....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
... Works includes everything from the care ... fuse, Spare Fluorescent Bulb, additional Vibratome ... Blocks, and a Specimen Tray. ... stage, 1/2" speciment mounts, replacement rotating ...
Medicine Products: